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Introduction
Poor cellular immune function may relate to carcino-
genic processes and to worse prognosis in solid tumor
patients as well as in leukemia. Moreover, the progres-
sion of tumor might further induce the cellular immune
suppression. Therefore, a set of molecular immunological
techniques to analyze and monitor the changes of host
T-cell immune status is needed, which can fully charac-
terize the feature of T-cell immunodeficiency in different
malignancies, providing information and direction for
immune reconstruction, in particular for enhancement
the specific anti-tumor immune function.
The feature of T-cell immunodeficiency in
hematological malignancies
In recent years, molecular analysis of the T cell receptor
(TCR) utilization feature based on the principle of TCR
a, b, g and δ gene rearrangement and deletion rearrange-
ment, has proven to be an effective technique for study-
ing the distribution of T cell repertoire, the diversity of
TCR subfamilies [1,2], the antigen specific expansion of
T-cell clones and the recent thymic output function [3,4].
This in turn can help to characterize the feature of host
T cell immune status, the identification of T-cell popula-
tions of interest in cancer, as well as the peripheral
immune repertoire reconstitution after hematopoietic
stem cell transplantation (HSCT).
T-cell immunodeficiency is a common feature in dif-
ferent hematological malignancies, including the absence
of TCR Va and Vb subfamilies, decreased diversity of
TCR repertoires, reduced thymic recent output function
(naïve T cells) and lower frequencies of TCR subfamily
naïve T cells. An impaired thymic export function and,
as a consequence, altered ability to maintain T cell
homeostasis may play an important pathogenic role in
hematological malignancies. On the other hand, clonally
expanded T cells could be identified in some TCR sub-
families in leukemia patients, which display specific anti-
leukemia cytotoxicity like WT1 or BCR-ABL specific
CTL, indicating that specific anti-leukemic T cells could
be generated in vivo. This suggests that the host could
have the ability of specific immune response to leukemia
associated antigens, despite of T cell immunodeficiency.
T-cell immune reconstitution and establishment
of specific anti-tumor and virus immunity
Prolonged period of immunodeficiency and poor immune
reconstitution after stem cell transplantation place patients
at high risk for viral infection and disease relapse, resulting
in significant morbidity and mortality. Reversion of the
cellular immunodeficiency is one of the crucial steps for
improvement the outcome of tumor therapy in hematolo-
gical malignancies. Moreover, the T-cell immune reconsti-
tution is a key determinacy of long-term outcome in
patients with hematological malignancies post chemother-
apy or stem cell transplantation.
T-cell immune reconstitution requests not only the
recovery of the comprehensive T-cell immunity, a broad
TCR repertoire and recent thymic emigrants, more
importantly, also the enhancement of the specific anti-
tumor cellular immune function, which plays determi-
nant role on elimination of minimal residual disease,
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provided the original work is properly cited.relapse prevention and improvement of prognosis in
hematological malignancies. Antigen specific T-cell
immune reconstitution could be carried out by active
(cancer vaccine) or adoptive immunotherapy (T-cells
transfusion) [5-8]. Cancer vaccines induce expansion
and functional differentiation of tumor antigen-specific
effectors and memory cells. The latter are particularly
relevant for prevention of disease relapse. Adoptive anti-
gen specific immunotherapy is one of the best
approaches for tumor immunotherapy. The antigen spe-
cific CTL can directly kill tumor cells, ignoring the host
immune status.
Antigen specific CTL could be amplified by cellular or
gene engineering techniques. Peptide -specific stimula-
tion in vitro can induce high-affinity CTL (auto- or allo-
genetic) capable of recognizing tumor cells expressing
the appropriate tumor antigen. For example, Epstein-
Barr virus (EBV)-specific CTL were used to treat the post
transplantation lymphoproliferative disease (PTLD) or
EBV+ lymphoma, CMV-specific CTL were used to estab-
lish anti-CMV immunity in immunodeficiency patients
post allogeneic stem cell transplantation [9,10]. Geneti-
cally-modified CTL were obtained by engineering antigen
specific TCR gene, thus altering their original antigen
specificity and arming them with new cytotoxicity for
tumor cells. The approach provides a new strategy for
adoptive specific immunotherapy in malignancies and so
on. A lot of TCR-modified CTL against different leuke-
mia and lymphoma were developed, like mHagHA-2,
EBV, WT1, CML or DLBCL-specific TCR modified CTL
[5-8,11,12], as well as the single-chain antibody-derived
chimeric antigen receptors (CARs) modified T cells that
specifically recognize surface molecules expressed on
malignant B cells (CD19) or acute myeloid leukemia cells
(CD33) independent from HLA [13,14].
In summary, dynamic detection of the alteration of
host immune function in patients is important for the
defense of host against neoplastic transformation and so
on. The new techniques of tumor immunology, molecu-
lar biology and increased knowledge of the optimal
methodology for generation of T-cell products and opti-
mization of gene therapy approaches make it possible to
enhance the function of adoptively transferred T cells.
This enhances tumor- specific response and can reverse
the host immunodeficiency status.
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